Through 2020, Growth in the Parkinson’s Disease Drug Market Will Be Constrained by Generic Competition to Key Therapies
Overall Market Sales Will Decrease Slightly, From $2.7 Billion in 2010 to $2.6 Billion in 2020, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, the Parkinson’s disease (PD) drug market will be constrained by generic competition to key therapies. Through 2020, the key PD therapies that will lose patent protection are Novartis/Orion Pharma’s Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck’s Azilect/Agilect, while ropinirole (GlaxoSmithKline’s Requip, generics; GlaxoSmithKline/SkyePharma’s Requip XL/LP/RP/Modutab/Prolib, generics) and pramipexole (Boehringer Ingelheim’s Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER/Sifrol Retard) will face increasing generic competition.
The findings from the Pharmacor topic entitled Parkinson’s Disease reveal that overall sales in this market will decrease slightly from $2.7 billion in 2010 to $2.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Most sales will continue to be driven by the leading dopamine agonists, pramipexole and ropinirole, and by increasing use of the MAO-B inhibitor Azilect/Agilect, as well as by the reentry of UCB/Schwarz Pharma’s Neupro/Leganto to the U.S. market and its wider use in Europe. Despite some key current therapies experiencing increased uptake during the forecast period and the launch of three new agents by 2020, sales of current agents and the market impact of emerging therapies will be offset by generic competition.
The three emerging therapies set to launch through 2020 are Impax Laboratories/GlaxoSmithKline’s IPX-066, a reformulation of the mainstay of PD therapy, levodopa (multiple brands, generics), Merck Serono/EMD Serono/Newron Pharmaceuticals’ MAO-B inhibitor safinamide and Kyowa Hakko Kirin’s adenosine A2A receptor antagonist istradefylline. IPX-066, and to a lesser extent safinamide, will contribute moderately to market growth, as both will contend with established agents within the same respective drug classes (which are often generically available), and that are commonly used in the patient populations targeted by the emerging therapies. The first-in-class agent istradefylline will benefit from use in the management of motor response complications arising from levodopa treatment, but its overall impact will be modest as it is currently expected to launch only in Japan.
“As we do not expect major shifts in the treatment paradigm of Parkinson’s disease over the next ten years, by 2020, the genericization of several key Parkinson’s disease therapies will depress market growth,” said Decision Resources Analyst Nadja Rozovsky, Ph.D. “Future therapies will need to clearly demonstrate superiority over current therapies to gain a competitive edge in this mature market.”
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders
Christopher Comfort, 781-993-2597
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Mental Health Pharmaceutical Other Health Research Science General Health